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Summary and Implications
     Intravenous immunoglobulin (IVIG) products improve
passive immunity in neonates.  Unfortunately, adverse
reactions can occur. This study was designed to determine if
physiological changes occurring after IVIG administration
were the result of rapid infusion of large molecular weight
molecules, or from a more complex mechanism resulting in
histamine release. The IVIG was concentrated from bovine
abattoir blood and contained approximately 35 g IgG/L. A
dextran (75,000 MW) solution was prepared as a high
molecular weight control that was similar in osmolarity to
the IVIG. Holstein bull calves (n=15) under 1 wk of age
were assigned to one of three treatment groups: control
calves received 500 ml of 0.9% NaCl; dextran calves
received 500 ml of dextran; IgG calves received 500 ml of
IVIG. Treatments were rapidly administered (less than 5
min) intravenously via jugular catheter. Heart rate,
respiration rate, and blood pressure were measured prior to
treatment, and at 1, 3, 5, 10, 15, 20, 25, 30, 45, 60, 75,
and 90 min after start of infusion. Blood samples were
obtained at the same sampling times, centrifuged, and the
plasma immediately placed on ice for determination of
histamine concentration using an enzyme immunoassay.
Mean respiration rates were higher in calves treated with
IVIG compared to calves in the other two groups at all time
periods measured. Mean heart rates were lower in calves
treated with IVIG compared to calves in the other groups
through 45 min. Calves treated with dextran had higher
mean heart rates than calves on the control treatment from
10 min through 30 min. Mean blood pressure tended to be
higher in calves treated with IVIG compared to calves on the
control treatment at 1 min, however, there were no
differences between groups at any other time period. Mean
histamine concentrations were higher in calves treated with
IVIG compared to calves on the control treatment at 1 min,
but were not different at any other time period. These data
indicate that adverse reactions to IVIG in calves are not
mediated by high molecular weight molecules or by
histamine release.
Introduction
     Calves are essentially agammaglobulinemic at birth,
although a small percentage of calves may have negligible
amounts of circulating serum IgG1, IgG2, IgM, and IgA. In
ruminants, passive immunity is provided through ingestion
of colostrum by the neonate after birth. Colostrum is vital
to the health and survival of the neonatal calf, and 18% of
cows provide colostrum with less than 100 g of IgG, the
most commonly recommended amount needed to prevent
failure of passive transfer (FPT). Colostrum-deprived calves
are 50-75 times more likely to die before 21 d of age than
colostrum-fed calves, with most deaths occurring during the
first week of life.
Oral colostral supplements and replacers are available
and can be offered when either the dam’s or some other fresh
or frozen colostrum source is not available; however, the
calf small intestine is unable to absorb intact IgG molecules
after approximately 26 h of age. Once the period of
intestinal permeability to immunoglobulin molecules has
passed, passive immunity can be provided by i.v., i.p., or
s.c. injection. Intravenous infusions of a bovine plasma
product in calves can increase serum IgG approximately 2.9
g/L.
Unfortunately, adverse reactions to intravenous
immunoglobulin (IVIG) administration can occur and have
been reported to occur in approximately 25-55% of foals, a
species where IVIG products are commonly used to treat
FPT. The incidence rate for reactions in foals appears to be
related to product IgG concentration and method of
production, with infusion of lyophilized IgG products
resulting in an increased rate of reactions. Intravenous
immunoglobulin products are also commonly used in
human medicine to treat a variety of disorders, and adverse
reactions are reported to be due to anaphylaxis, complement
activation, vasoactive properties of the infusion product, or
other unknown.
Clinical signs of adverse reactions and the mechanism
of action causing these reactions have not been documented
in calves receiving IVIG. Therefore, this study was designed
to characterize adverse reactions to IVIG in calves, and to
determine if physiological changes occurring after IVIG
administration were the result of rapid infusion of large
molecular weight molecules or were due to a more complex
mechanism resulting in histamine release.
Procedures
     Fifteen Holstein bull calves under one week of age were
assigned to one of three treatment groups. The treatment
groups were: (1) Control, calves received 500 ml of 0.9%
NaCl; (2) Dextran, calves received 500 ml of a dextran
solution; and (3) IgG, calves received 500 ml of an IVIG
product. The dextran solution was prepared by adding 10 g
of dextran powder (75,000 MW) to 500 ml of a NaCl
solution. The dextran solution was prepared so that the
osmolarity of the solution (269 mOsm) was similar to that
of the concentrated plasma product (277 mOsm). The IVIG
product was prepared from plasma obtained after a two-time
enrichment process of bovine abattoir blood, with the final
product containing approximately 35 g IgG/L. Previous
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analysis showed that the product had low endotoxin levels,
and low complement activity.
Catheters were aseptically placed in each jugular vein so
that the treatment could be administered through one, while
blood samples were obtained from the other. A catheter was
also placed in an ear artery and connected to a manometer
for arterial blood pressure monitoring.
Calf heart rate, respiration rate, and mean arterial blood
pressure were measured prior to the start of treatment
infusion, and then at 1, 3, 5, 10, 15, 20, 25, 30, 45, 60,
75, and 90 min after the start of the infusion. Blood
samples were collected into tubes containing EDTA at the
same sampling times, centrifuged, and the plasma
immediately placed on ice for determination of histamine
concentration.
The amount of histamine present in plasma was
determined using a commercially available ELISA
(Immunotech, Marseille, Cedex 9, France).
Experimental data were analyzed using the general
linear models procedure of SAS (SAS Inst. Inc., Cary, NC).
Multiple measurements recorded over time were analyzed
using the mixed procedure with calf within treatment
interaction used as the random statement. Significance was
declared at P < 0.05 and trends towards significance at P >
0.05 to P < 0.10.
Results and Discussion
     Two calves died within 30 minutes after the infusion of
IVIG, therefore, they were excluded from the results, and
least squares means are reported. There was an overall
treatment effect (P < 0.001), an overall time effect (P <
0.001), and a time by treatment effect (P < 0.001) for
respiration rate (Figure 1). Mean respiration rates were not
different among treatments prior to the start of infusions,
but were higher in IgG calves compared to calves in the
other two groups at all other time periods measured.
Respiration rate also showed a large increase after the start
of the infusion in calves receiving IVIG, whereas respiration
rate remained more or less constant in calves on the other
two treatments.
There was no overall treatment effect for heart rate
(Figure 2), however, there was a time effect (P < 0.001) and
a time by treatment effect (P < 0.001). Mean heart rates
were not different among treatments prior to the start of the
infusions, however, heart rates decreased in calves receiving
IVIG, and were lower compared to calves in the other two
groups through 45 min. post infusion. Heart rates increased
in both control and dextran calves, and dextran calves had
higher mean heart rates compared to control calves from 10
min. through 30 min. post infusion.
There was no overall treatment effect for mean arterial
blood pressure (Figure 3), however there was a time effect
(P < 0.001) and there tended to be a time by treatment effect
(P < 0.07). Mean arterial blood pressure was not different
among treatments prior to the start of the infusions, nor was
it significant between treatment groups at any other time
period measured. After the start of the infusion, blood
pressure increased initially and then decreased rapidly in IgG
calves. In contrast, calves receiving the other two treatments
had a more gradual increase and then decrease in arterial
blood pressure.
Mean histamine concentrations (Figure 4) were not
different among treatments prior to the start of the
infusions, nor were they significant between treatment
groups at any other time period measured.
The IVIG product utilized in this trial consistently
caused clinical signs of infusion reactions in all calves.
Within seconds after the start of the infusion, calves showed
increases in respiration rate and became increasingly dull
and lethargic. In contrast, calves receiving the dextran and
saline solutions showed no visible clinical signs of
discomfort, although they did show increases in heart rate.
The increase in heart rate is likely due to expansion in fluid
volume, and could be attributed to the rapid infusion of
large molecular weight molecules in the dextran group.
There are three ways by which exposure to a substance
can cause anaphylaxis: 1. exposure to a foreign protein that
results in IgE antibody formation. Reexposure results in IgE
mediated degranulation of mast cells and basophils; 2.
formation of immune complexes that activate the
complement cascade; and 3. administration of certain agents
(hyperosmolar solutions, radiocontrast agents, etc.) that
directly stimulate the release of mediators by unknown
mechanisms. Classic anaphylactic reactions are defined as
resulting from a Type I immune response, also called
immediate hypersensitivity. This type of reaction requires
three components: 1. an antigen; 2. IgE antibody; and 3.
effector cells such as mast cells and basophils that
synthesize and release pharmacologic mediators. Reactions
that appear clinically similar to anaphylactic reactions, but
are not mediated by IgE are referred to as anaphylactoid
reactions. Because the calves on this trial did not have
previous exposure to IVIG, it is unlikely that the observed
reactions were mediated by IgE. Therefore, the observed
reactions will be classified as anaphylactoid reactions for the
remainder of this discussion.
Increased histamine concentrations are often observed in
anaphylactic and anaphylactoid reactions. However, some
studies do report increased histamine levels after challenge
in control mice, while others report no change in histamine
levels before or after anaphylaxis in both control and mast
cell deficient mice. Hypotension and death due to
anaphylactic reactions in mice also do not appear to require
mast cell-derived mediators. Adverse reactions to IVIG in
humans have also been shown to be associated with
increases in IL-6 and thromboxane B2, but not change in
blood pressure, kininogen, histamine, or tryptase.
     Concentrations reported for histamine in this study were
well within the normal range. Plasma histamine
concentrations were never greater than 3 nM histamine.
Mean whole blood values for histamine in 1-week old
calves are 173 nM. Whole blood histamine concentrations
are generally 20 – 200 times greater than plasma histamine
concentrations.
Administration of contrast media and hyperosmolar
solutions to humans can also cause reactions similar to
those observed from infusion of IVIG. However, the
osmolarity of the dextran and the IVIG solution were both
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similar to the osmotic pressure in calves. The osmotic
pressure in newborn calves is 293 mOsm/L and decreases to
286 mOsm/L after feeding. Thus, hyperosmolarity is not
the cause of the anaphylactoid reactions observed in these
calves.
     These data indicate that the adverse reactions to IVIG
observed in this trial are not mediated by high molecular
weight molecules or by the release of histamine. Further
research is needed to determine the role of platelet activating
factor in anaphylactoid reactions in calves.
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Figure 1. Mean respiration rates for calves receiving saline, dextran, or intravenous immunoglobulin.
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Figure 2. Mean heart rates for calves receiving saline, dextran, or intravenous immunoglobulin.
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Figure 3. Mean arterial blood pressure for calves receiving saline, dextran, or intravenous immunoglobulin.
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Figure 4. Mean histamine concentration for calves receiving saline, dextran, or intravenous immunoglobulin.
